Data from recent clinical trials and basic research show a potential role for SGLT2 inhibitors in treating obesity-associated cardiometabolic complications targeting those abnormal pathophysiological systems in PCOS. Here, SLC5A2 is linked to obesity due to melanocortin 4 receptor deficiency.